Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil and Minocycline for Chemoradiation Symptoms in Esophageal Cancer
NCT01746043Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2013
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of armodafinil and minocycline in fatigue, pain, sleep disorder and 2 more (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Proportion of Patients with Mean Symptom Increase of 2 Units or More at 6 weeks. Started Feb 2013; status: completed.
02
Drugs
armodafinilminocycline
03
Conditions
fatiguepainsleep disorderanorexia nervosa (AN)somnolence
Beyond the preview
Go deeper on NCT01746043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746043.